Superantigenic toxin type No of isolates from Odds ratio 95% Confidence interval P value (fisher exact test) P C
patients with mild AD (total n=28) n/(%) patients with moderate to severe AD (total n=31) n/(%)
SEA 05 (17.8) 10 (32) 2.19 0.7026 to 4.645 0.24 4.13
SEB 04 (14.3) 4 (12.9) 0.89 0.2490 to 3.277 1.00 17.00
SEC 07 (25.0) 8 (25.8) 1.04   1.00 17.00
SED 05 (17.9) 4 (12.9) 0.68 0.1634 to 2.842 0.72 12.29
SEE 04 (14.3) 5 (16.1) 1.15 0.3361 to 3.793 1.00 17.00
SEG 13 (46.4) 10 (32.3) 0.55 0.3638 to 1.327 0.29 5.04
SEH 00 (0) 00 (0)       0.00
SEI 13 (46.4) 13 (41.9) 0.83 0.5085 to 1.604 0.79 13.53
SEJ 02 (7.1) 3 (9.7) 1.39   1.00 17.00
SElK 03 (10.7) 4 (12.9) 1.23   1.00 17.00
SElL 01 (3.6) 5 (16.1) 5.40   0.20 3.36
SElM 17 (60.7) 10 (32.3) 0.31 0.2943 to 0.9593 0.04 0.65
SElN 12 (42.9) 9 (29) 0.55 0.3373 to 1.360 0.30 4.95
SElO 14 (50) 6 (19.4) 0.24 0.1724 to 0.8689 0.01 0.27
SElP 05 (17.9) 4 (12.9) 0.68   0.72 12.29
SElQ 03 (10.7) 4 (12.9) 1.39   1.00 17.00
TSST-1 06 (21.4) 6 (19.4) 0.88   1.00 17.00
Table 2: Association of superantigen production with severity of atopic dermatitis (AD).